Using Donepezil for Cognitive Changes in Parkinson’s

Donepezil, best known as an Alzheimer’s medicine, is also prescribed to many people whose Parkinson’s has begun to affect memory and thinking. For people with Parkinson’s dementia, it tends to bring a modest lift in thinking and daily function rather than a dramatic turnaround.¹ The picture is less clear for milder thinking changes, where the drug’s benefit hasn’t been proven.² How it is stopped matters as much as how it is started.

Why A Dementia Drug Is Used In Parkinson’s

Parkinson’s is known for the loss of dopamine, which drives the tremor, stiffness and slowness. But the disease also damages nerve fibres that carry acetylcholine, a chemical messenger for memory and attention, to the brain’s outer layer and its memory centre.³ Losing these fibres is linked to the thinking problems of Parkinson’s.⁴ When those problems become severe enough to get in the way of daily life, doctors call it Parkinson’s disease dementia.

These problems don’t look quite like Alzheimer’s. Parkinson’s dementia often hits attention, planning and speed of thought before memory, and visual hallucinations are common early on. A person may seem easily distracted, lose the thread of a conversation or struggle to switch between tasks, which can look like disinterest rather than illness. Jobs that need planning, such as managing pills, cooking a meal in sequence or handling bills, often become hard before names or recent events are forgotten. Thinking can also fluctuate, with clearer days and foggier ones.

Donepezil blocks the chemical that breaks down acetylcholine between nerve cells, so more of it stays available to carry signals.⁵ It reaches the brain directly, where the shortage is greatest.⁶ Its effect lasts long enough that one tablet a day is enough.

It is a boost, not a cure. It doesn’t repair lost nerve fibres or stop Parkinson’s from progressing, and it doesn’t replace levodopa or other movement medicines. If the drug is stopped, the benefits fade.

How Much Improvement To Expect

Doctors often track thinking with the MMSE, a 30-point memory and thinking test you may see in clinic notes. People with Parkinson’s dementia on donepezil scored about 2 points better on it than on a dummy pill.⁷ Doctors’ overall ratings of how the person was doing also improved slightly.⁸

On a 30-point scale, 2 points is a small average shift. It won’t bring back earlier abilities, so the realistic goal is somewhat steadier thinking. Scores wobble from day to day with tiredness, mood and the time of the last dose of Parkinson’s medicine, so a single score says little.

Not everyone responds. In one trial about 4 in 10 people on donepezil were rated improved, versus under 2 in 10 on a dummy pill.⁹ In a larger trial, only the 10 mg dose clearly beat a dummy pill on overall ratings.¹⁰ That trial didn’t meet its main goals, so the evidence is real but not overwhelming.¹¹

Donepezil has also improved attention and mental flexibility, such as quickly naming words, in Parkinson’s dementia.¹² People on a dummy pill tended to get worse over the same period.¹³

At home, a 2-point change may show up as following conversations more easily, finishing a TV programme or staying with a task for longer. Families tend to see more alertness rather than better recall of facts, and memory for past events may look much the same, which can feel disappointing even when attention has improved. Because the benefit is subtle, it is often clearest in hindsight, for instance when things slip after a missed stretch of doses.

Trials judged effects after about 10 weeks to several months, so that is a fair time to try it before deciding. Doses usually start at 5 mg and may rise to 10 mg. Keeping notes on alertness, hallucinations and daily tasks gives the doctor something concrete to work with, and it helps to ask at the start what change the doctor hopes to see.

Effects On Hallucinations And Movement

Medicines in donepezil’s class slightly reduce hallucinations and false beliefs in Parkinson’s.¹⁴ In some people, donepezil has made visual hallucinations go away without worsening movement.¹⁵ But in one reported case, false beliefs appeared during treatment and faded when the drug was stopped.¹⁶ So any new suspicious or false beliefs should be reported promptly. Distressing hallucinations or paranoia need prompt review, and the doctor should also check for other causes, such as an infection or a recent medicine change.

Movement is the other worry. Donepezil improved thinking and hallucinations without increasing Parkinson’s movement symptoms.¹⁷ That matters because many antipsychotic drugs worsen stiffness and slowness in Parkinson’s.

Side effects are mostly digestive. Nausea, loose stools and reduced appetite are the most common problems, usually worst when starting or raising the dose, and taking the tablet with food may help. Vivid dreams or disturbed sleep can occur, and the doctor may suggest taking it in the morning instead of at night. Donepezil can slow the heart rate, so dizziness, fainting or a very slow pulse should be reported rather than put down to Parkinson’s. Parkinson’s already raises the risk of falls, so any new fall or near-fall after starting or changing the dose is worth mentioning promptly.

Mild Thinking Changes Before Dementia

Mild cognitive impairment means noticeable thinking changes that don’t yet disrupt daily life. In people with Parkinson’s and these mild thinking changes, donepezil didn’t improve thinking compared with a dummy pill.¹⁸ German neurology guidelines advise against these drugs at this stage.¹⁹ That reflects a lack of proof of benefit, not proof of harm. Taking the drug then means accepting side effects without a proven gain, so if a doctor still suggests it, ask what they hope to see and how it will be judged.

Prevention is a separate question. In people with Parkinson’s and a badly reduced sense of smell, who face higher dementia risk, about 7% on donepezil developed dementia over several years versus 12% on a dummy pill.²⁰ That difference could have been chance.²¹ After four years, the donepezil group scored better on thinking and daily-function ratings.²² Those results come from a specific group, so they may not apply to everyone with Parkinson’s. Starting early versus later made a clear difference only in people carrying a particular gene variant linked to dementia risk.²³

Meanwhile, there are practical steps. Regular exercise and staying socially and mentally active are widely recommended and carry few downsides. The doctor or pharmacist can review medicines that can dull thinking, such as some bladder and sleep drugs, since changing them can help clarity. Repeat thinking tests at set intervals mean any decline is noticed early, and the question of donepezil can be revisited then.

Why Stopping Suddenly Can Backfire

Stopping donepezil suddenly can cause a rapid drop in thinking and behaviour in Parkinson’s dementia.²⁴ Restarting it generally reverses this decline.²⁵ In another small trial, all three people with Parkinson’s dementia worsened when their drug stopped and improved after restarting.²⁶ So don’t stop it on your own; plan any change with the doctor. After a sudden stop, family may see more confusion, drowsiness or agitation, along with slower thinking, over days to weeks.

A decline after stopping can show the drug was helping, which is useful when deciding whether to continue. Someone who has declined overall may still be getting benefit, since the drug aims to slow loss rather than reverse it. If stopping is being considered because of cost, pill burden or lack of visible change, discuss it with the doctor first and agree on how to watch for changes.

Sometimes stopping can’t be avoided. If side effects such as a slow heart rate, fainting or severe stomach upset force a stop, ask whether lowering the dose gradually is possible and how closely the person will be followed. Agree beforehand on warning signs, such as new confusion or hallucinations, and on who to call to restart quickly. If surgery or a hospital stay interrupts doses, tell the team that donepezil should be resumed so it isn’t left off by accident.

Donepezil Compared With Other Options

Rivastigmine improved thinking and other measures in a large Parkinson’s dementia trial, and it is widely approved for mild to moderate Parkinson’s dementia.²⁷ Donepezil is used outside its official approval, and guidelines accept this.²⁸

Day to day, the drugs differ in form. Donepezil is a once-daily tablet, while rivastigmine comes as capsules taken twice daily or as a skin patch. The patch may suit people who get stomach upset or have trouble swallowing, since it gives a steadier dose through the skin. If one drug isn’t tolerated, doctors can switch to the other, as they act in a similar way. Because donepezil is used outside its official approval, coverage can vary, so check with the pharmacy.

Memantine is another option. In Alzheimer’s, adding memantine to donepezil worked better than either alone.²⁹ That comes from Alzheimer’s, not Parkinson’s, so it can’t be assumed to carry over.